Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management, allowing for investment in low-risk financial products while ensuring that the funds are not diverted from their intended projects [1][3][5]. Fund Management and Usage - The company has established a special account for managing raised funds, with all funds deposited into this account upon receipt [2]. - The total amount of raised funds for investment projects is approximately 277.88 million RMB [2]. Cash Management Details - The company will manage up to 1 billion RMB of temporarily idle raised funds, investing in low-risk products such as structured deposits and time deposits, with a maximum investment period of 12 months [1][3][4]. - The cash management decision is valid for 12 months from the board's approval date, and the 1 billion RMB can be used in a rolling manner [4]. Investment Purpose and Products - The objective of cash management is to enhance the efficiency of fund usage and increase company returns without affecting the ongoing investment projects [3][5]. - The company will strictly control risks and will not use the funds for pledging or securities investment [3][4]. Operational Impact - The cash management strategy will not impact the company's main business operations or the progress of investment projects, aiming to improve fund efficiency and shareholder returns [5][7]. - The company will adhere to relevant accounting standards for financial instruments in managing these funds [5]. Approval and Compliance - The board of directors approved the cash management plan on May 29, 2025, ensuring compliance with regulatory requirements [7][8]. - The sponsor institution has confirmed that the plan aligns with regulatory guidelines and does not conflict with the company's investment project implementation [8].
诺诚健华: 诺诚健华医药有限公司关于使用部分暂时闲置募集资金进行现金管理及以通知存款、协定存款等方式存放募集资金的公告